Circulating tumor DNA predicts prognosis at different time points in patients with esophageal cancer: a systematic review and meta-analysis.

ABSTRACT:

Background

Circulating tumor DNA (ctDNA), as a liquid biopsy biomarker, is undergoing extensive evaluation for its clinical utility across multiple tumor management scenarios. This study aimed to assess the prognostic value of ctDNA in esophageal cancer (EC) patients at different treatment time points through a systematic review and meta-analysis.

Materials and methods

A comprehensive search of the PubMed, Embase, and Cochrane Library databases from construction to October 2024 was conducted, and studies investigating the association between ctDNA and progression-free survival (PFS) and overall survival (OS) in EC patients were screened for inclusion. Primary outcomes included PFS/OS by ctDNA status at different time points (baseline, after neoadjuvant therapy, and during fo

SUBMITTER: Wang M 

PROVIDER: S-EPMC12507613 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature